image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.75
-0.186 %
$ 17.9 M
Market Cap
-0.51
P/E
1. INTRINSIC VALUE

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services.[ Read More ]

The intrinsic value of one PRPH stock under the base case scenario is HIDDEN Compared to the current market price of 0.75 USD, ProPhase Labs, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PRPH

image
FINANCIALS
44.4 M REVENUE
-63.81%
-21.6 M OPERATING INCOME
-91.60%
-16.8 M NET INCOME
-90.90%
-11.3 M OPERATING CASH FLOW
-39.75%
-1.37 M INVESTING CASH FLOW
34.09%
5.76 M FINANCING CASH FLOW
122.12%
3.15 M REVENUE
27.16%
-7.94 M OPERATING INCOME
-1.41%
-6.59 M NET INCOME
-7.05%
-4.03 M OPERATING CASH FLOW
16.36%
-97 K INVESTING CASH FLOW
-78.23%
-7.59 M FINANCING CASH FLOW
-142.66%
Balance Sheet Decomposition ProPhase Labs, Inc.
image
Current Assets 47.6 M
Cash & Short-Term Investments 4.74 M
Receivables 36.3 M
Other Current Assets 6.54 M
Non-Current Assets 44.3 M
Long-Term Investments 0
PP&E 17.5 M
Other Non-Current Assets 26.9 M
Current Liabilities 20.9 M
Accounts Payable 9.38 M
Short-Term Debt 2.79 M
Other Current Liabilities 8.68 M
Non-Current Liabilities 21.7 M
Long-Term Debt 18.6 M
Other Non-Current Liabilities 3.1 M
EFFICIENCY
Earnings Waterfall ProPhase Labs, Inc.
image
Revenue 44.4 M
Cost Of Revenue 28.1 M
Gross Profit 16.2 M
Operating Expenses 37.9 M
Operating Income -21.6 M
Other Expenses -4.83 M
Net Income -16.8 M
RATIOS
36.59% GROSS MARGIN
36.59%
-48.70% OPERATING MARGIN
-48.70%
-37.81% NET MARGIN
-37.81%
-33.98% ROE
-33.98%
-18.26% ROA
-18.26%
-26.67% ROIC
-26.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ProPhase Labs, Inc.
image
Net Income -16.8 M
Depreciation & Amortization 6.7 M
Capital Expenditures -3.16 M
Stock-Based Compensation 3.54 M
Change in Working Capital -5.7 M
Others -9.13 M
Free Cash Flow -14.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ProPhase Labs, Inc.
image
PRPH has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.3 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ProPhase Labs, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 years ago
Mar 10, 2022
Bought 4.67 K USD
Barr Jason Michael
Director
+ 721
6.48 USD
2 years ago
Mar 10, 2022
Bought 4.86 K USD
Barr Jason Michael
director:
+ 750
6.48 USD
3 years ago
Jun 03, 2021
Bought 172 K USD
Karkus Ted William
CEO & CHAIRMAN
+ 33943
5.065 USD
4 years ago
Aug 13, 2020
Sell 138 K USD
Karkus Ted William
CEO & CHAIRMAN
- 50000
2.75 USD
4 years ago
Aug 13, 2020
Bought 138 K USD
GLECKEL LOUIS MD
Director
+ 50000
2.75 USD
4 years ago
Mar 26, 2020
Bought 175 K USD
GLECKEL LOUIS MD
Director
+ 100000
1.75 USD
4 years ago
Mar 26, 2020
Sell 175 K USD
Karkus Ted William
CEO & CHAIRMAN
- 100000
1.75 USD
5 years ago
Oct 01, 2019
Bought 5.63 K USD
Barr Jason Michael
Director
+ 2870
1.96 USD
5 years ago
Aug 15, 2019
Bought 5.12 K USD
Barr Jason Michael
Director
+ 2500
2.05 USD
5 years ago
Aug 14, 2019
Bought 12.3 K USD
Barr Jason Michael
Director
+ 6000
2.05 USD
6 years ago
Dec 21, 2017
Sell 977 K USD
Karkus Ted William
CEO & CHAIRMAN
- 424789
2.3 USD
7 years ago
Sep 29, 2017
Sell 3.9 M USD
Leonard Braden Michael
10 percent owner
- 1695305
2.3 USD
7 years ago
Sep 29, 2017
Sell 10.1 K USD
Barr Jason Michael
Director
- 4379
2.3 USD
7 years ago
Sep 29, 2017
Sell 825 K USD
CUDDIHY ROBERT V JR
Chief Financial Officer
- 358621
2.3 USD
7 years ago
Sep 29, 2017
Sell 839 K USD
Karkus Ted William
CEO & CHAIRMAN
- 364950
2.3 USD
8 years ago
Nov 30, 2015
Bought 1.4 K USD
Leventhal Mark S
Director
+ 948
1.48 USD
8 years ago
Nov 27, 2015
Bought 20.6 K USD
Leventhal Mark S
Director
+ 13300
1.55 USD
8 years ago
Nov 25, 2015
Bought 22.4 K USD
Leventhal Mark S
Director
+ 17252
1.3 USD
8 years ago
Nov 24, 2015
Bought 24 K USD
Leventhal Mark S
Director
+ 18500
1.3 USD
9 years ago
Jun 04, 2015
Bought 260 K USD
Karkus Ted William
See Remarks
+ 200000
1.3 USD
9 years ago
May 19, 2015
Bought 269 K USD
Karkus Ted William
CEO & Chairman
+ 199504
1.35 USD
9 years ago
May 18, 2015
Bought 14.1 K USD
Karkus Ted William
CEO & Chairman
+ 10496
1.34 USD
10 years ago
Nov 07, 2014
Bought 19.2 K USD
Leonard Braden Michael
10 percent owner
+ 13946
1.38 USD
10 years ago
Nov 06, 2014
Bought 10.3 K USD
Leonard Braden Michael
10 percent owner
+ 7500
1.37 USD
10 years ago
Nov 05, 2014
Bought 57.2 K USD
Leonard Braden Michael
10 percent owner
+ 43300
1.32 USD
10 years ago
Oct 09, 2014
Bought 221 K USD
Leonard Braden Michael
10 percent owner
+ 169975
1.3009 USD
10 years ago
Oct 08, 2014
Bought 149 K USD
Leonard Braden Michael
10 percent owner
+ 114910
1.2986 USD
10 years ago
Oct 02, 2014
Bought 23.6 K USD
Leonard Braden Michael
10 percent owner
+ 16900
1.3977 USD
10 years ago
Sep 24, 2014
Bought 6.35 K USD
Leonard Braden Michael
10 percent owner
+ 4538
1.4 USD
10 years ago
Sep 23, 2014
Bought 22.1 USD
Leonard Braden Michael
10 percent owner
+ 16
1.38 USD
10 years ago
Sep 22, 2014
Bought 61.7 K USD
Leonard Braden Michael
10 percent owner
+ 44042
1.4 USD
10 years ago
Sep 18, 2014
Bought 3.5 K USD
Leonard Braden Michael
10 percent owner
+ 2500
1.4 USD
10 years ago
Sep 16, 2014
Bought 14.1 K USD
Leonard Braden Michael
10 percent owner
+ 10000
1.41 USD
10 years ago
Sep 15, 2014
Bought 150 K USD
Leonard Braden Michael
10 percent owner
+ 103918
1.44 USD
10 years ago
Sep 12, 2014
Bought 5.39 K USD
Leonard Braden Michael
10 percent owner
+ 3409
1.58 USD
10 years ago
Sep 11, 2014
Bought 22.4 K USD
Leonard Braden Michael
10 percent owner
+ 14613
1.53 USD
11 years ago
Jun 25, 2013
Bought 246 K USD
Karkus Ted William
CEO & Chairman
+ 155480
1.58 USD
11 years ago
Jun 24, 2013
Bought 446 K USD
Karkus Ted William
CEO & Chairman
+ 286150
1.56 USD
11 years ago
Jun 23, 2013
Bought 88.1 K USD
Karkus Ted William
CEO & Chairman
+ 58370
1.51 USD
11 years ago
May 23, 2013
Bought 33 K USD
Frank Mark Shawn
Director
+ 20000
1.65 USD
11 years ago
May 09, 2013
Bought 2.09 K USD
Leventhal Mark S
Director
+ 1304
1.6 USD
11 years ago
May 08, 2013
Bought 13.9 K USD
Leventhal Mark S
Director
+ 8696
1.6 USD
11 years ago
Nov 30, 2012
Bought 1.29 K USD
MCCUBBIN JAMES T
Director
+ 834
1.55 USD
11 years ago
Nov 29, 2012
Bought 164 K USD
Leventhal Mark S
Director
+ 102700
1.6 USD
11 years ago
Nov 28, 2012
Bought 67.2 K USD
Leventhal Mark S
Director
+ 47300
1.42 USD
12 years ago
Sep 04, 2012
Sell 1.4 USD
QUIGLEY GUY J
10 percent owner
- 1
1.4 USD
12 years ago
May 17, 2012
Bought 109 K USD
Karkus Ted William
CEO & Chariman
+ 103402
1.05 USD
12 years ago
May 15, 2012
Bought 139 K USD
Karkus Ted William
CEO & Chariman
+ 141388
0.98 USD
13 years ago
Nov 16, 2011
Bought 17.3 K USD
Karkus Ted William
CEO & Chairman
+ 19192
0.899 USD
13 years ago
Nov 14, 2011
Bought 146 K USD
Karkus Ted William
CEO & Chairman
+ 171018
0.852 USD
13 years ago
Nov 14, 2011
Bought 86.5 K USD
Burnett Mark A.
Director
+ 100000
0.865 USD
13 years ago
Aug 23, 2011
Bought 85 USD
Burnett Mark A.
Director
+ 100
0.85 USD
14 years ago
Oct 01, 2010
Sell 3.3 K USD
QUIGLEY GUY J
10 percent owner
- 3000
1.1 USD
14 years ago
Oct 01, 2010
Sell 1.11 K USD
QUIGLEY GUY J
10 percent owner
- 1000
1.11 USD
14 years ago
Oct 01, 2010
Sell 1.11 K USD
QUIGLEY GUY J
10 percent owner
- 1000
1.11 USD
14 years ago
Oct 01, 2010
Sell 3.3 K USD
QUIGLEY GUY J
10 percent owner
- 3000
1.1 USD
14 years ago
Oct 01, 2010
Sell 1.11 K USD
QUIGLEY GUY J
10 percent owner
- 1000
1.11 USD
14 years ago
Oct 01, 2010
Sell 1.11 K USD
QUIGLEY GUY J
10 percent owner
- 1000
1.11 USD
18 years ago
Oct 26, 2006
Sell 300 K USD
QUIGLEY GUY J
Chairman, President, CEO
- 50000
6 USD
18 years ago
Oct 26, 2006
Sell 300 K USD
PHILLIPS CHARLES A
EVP, COO
- 50000
6 USD
18 years ago
May 08, 2006
Sell 250 K USD
QUIGLEY GUY J
Chairman, President, CEO
- 25000
10 USD
18 years ago
May 08, 2006
Sell 250 K USD
PHILLIPS CHARLES A
EVP, COO
- 25000
10 USD
18 years ago
Apr 05, 2006
Sell 2.47 M USD
QUIGLEY GUY J
Chairman, President, CEO
- 290125
8.5 USD
18 years ago
Apr 05, 2006
Sell 1.66 M USD
QUIGLEY GUY J
Chairman, President, CEO
- 194750
8.5 USD
18 years ago
Apr 05, 2006
Sell 2.47 M USD
PHILLIPS CHARLES A
EVP, COO
- 290125
8.5 USD
18 years ago
Mar 21, 2006
Sell 52.7 K USD
QUIGLEY GUY J
Chairman, President, CEO
- 5250
10.03 USD
18 years ago
Mar 21, 2006
Sell 99 K USD
PHILLIPS CHARLES A
EVP, COO
- 9875
10.03 USD
20 years ago
Nov 16, 2004
Sell 8.01 K USD
SCHAUM ROUNSEVELLE W
Director
- 1000
8.01 USD
20 years ago
Nov 17, 2004
Sell 36.7 K USD
SCHAUM ROUNSEVELLE W
Director
- 4487
8.17 USD
20 years ago
Sep 08, 2004
Sell 15.4 K USD
SCHAUM ROUNSEVELLE W
Director
- 2000
7.725 USD
20 years ago
Sep 09, 2004
Sell 22.3 K USD
SCHAUM ROUNSEVELLE W
Director
- 3000
7.4233 USD
20 years ago
Jun 22, 2004
Sell 8.16 K USD
SCHAUM ROUNSEVELLE W
Director
- 1000
8.16 USD
20 years ago
Apr 05, 2004
Sell 10 K USD
SCHAUM ROUNSEVELLE W
Director
- 1000
10.0155 USD
21 years ago
Aug 15, 2003
Sell 15.8 K USD
SCHAUM ROUNSEVELLE W
Director
- 2000
7.9 USD
21 years ago
Aug 18, 2003
Sell 28.1 K USD
SCHAUM ROUNSEVELLE W
Director
- 3500
8.035 USD
21 years ago
Aug 15, 2003
Sell 39.7 K USD
SCHAUM ROUNSEVELLE W
Director
- 5000
7.9456 USD
21 years ago
Aug 15, 2003
Sell 10.3 K USD
SCHAUM ROUNSEVELLE W
Director
- 1300
7.95 USD
21 years ago
Aug 15, 2003
Sell 30 K USD
SCHAUM ROUNSEVELLE W
Director
- 3800
7.9 USD
21 years ago
Aug 07, 2003
Sell 7.67 K USD
SCHAUM ROUNSEVELLE W
Director
- 1000
7.67 USD
7. News
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. seekingalpha.com - 1 day ago
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. zacks.com - 4 days ago
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024 GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. globenewswire.com - 6 days ago
ProPhase Labs Announces Pricing of Public Offering of Common Stock GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024, subject to satisfaction of customary closing conditions. globenewswire.com - 1 week ago
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025 Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 globenewswire.com - 1 month ago
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH) NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase's business model, services, industry, financial results, valuation, and risks and contains our most recent research and analysis of the company. globenewswire.com - 2 months ago
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. globenewswire.com - 2 months ago
ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation. seekingalpha.com - 3 months ago
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14 GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. globenewswire.com - 3 months ago
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. globenewswire.com - 4 months ago
ProPhase Labs, Inc. (PRPH) Q1 2024 Earnings Call Transcript ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2024 Earnings Conference Call May 9, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. seekingalpha.com - 6 months ago
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test. globenewswire.com - 6 months ago
8. Profile Summary

ProPhase Labs, Inc. PRPH

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 17.9 M
Dividend Yield 0.00%
Description ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Contact 711 Stewart Avenue, Garden City, NY, 11530 https://www.prophaselabs.com
IPO Date April 4, 1994
Employees 113
Officers Mr. Sergio Miralles Executive Vice President & Chief Information Officer Mr. Kamal Obbad Senior Vice President and Director of Sales & Marketing - Nebula Genomics Mr. Jed A. Latkin Chief Operating Officer & Head of Finance Department Mr. Lance Bisesar Corporate Controller Mr. Jason Karkus President of Nebula Genomics Mr. Ted William Karkus Chairman & Chief Executive Officer